<?xml version="1.0"?>
<feed xmlns="http://www.w3.org/2005/Atom" xml:lang="en">
		<id>http://www.colloquiam.com/wd/index.php?action=history&amp;feed=atom&amp;title=Cheng_et_al._2016aa</id>
		<title>Cheng et al. 2016aa - Revision history</title>
		<link rel="self" type="application/atom+xml" href="http://www.colloquiam.com/wd/index.php?action=history&amp;feed=atom&amp;title=Cheng_et_al._2016aa"/>
		<link rel="alternate" type="text/html" href="http://www.colloquiam.com/wd/index.php?title=Cheng_et_al._2016aa&amp;action=history"/>
		<updated>2026-05-14T03:55:55Z</updated>
		<subtitle>Revision history for this page on the wiki</subtitle>
		<generator>MediaWiki 1.27.0-wmf.10</generator>

	<entry>
		<id>http://www.colloquiam.com/wd/index.php?title=Cheng_et_al._2016aa&amp;diff=9556&amp;oldid=prev</id>
		<title>Scipediacontent: Scipediacontent moved page Draft Content 335065895 to Cheng et al. 2016aa</title>
		<link rel="alternate" type="text/html" href="http://www.colloquiam.com/wd/index.php?title=Cheng_et_al._2016aa&amp;diff=9556&amp;oldid=prev"/>
				<updated>2016-10-04T10:19:47Z</updated>
		
		<summary type="html">&lt;p&gt;Scipediacontent moved page &lt;a href=&quot;/public/Draft_Content_335065895&quot; class=&quot;mw-redirect&quot; title=&quot;Draft Content 335065895&quot;&gt;Draft Content 335065895&lt;/a&gt; to &lt;a href=&quot;/public/Cheng_et_al._2016aa&quot; title=&quot;Cheng et al. 2016aa&quot;&gt;Cheng et al. 2016aa&lt;/a&gt;&lt;/p&gt;
&lt;table class=&quot;diff diff-contentalign-left&quot; data-mw=&quot;interface&quot;&gt;
				&lt;tr style='vertical-align: top;' lang='en'&gt;
				&lt;td colspan='1' style=&quot;background-color: white; color:black; text-align: center;&quot;&gt;← Older revision&lt;/td&gt;
				&lt;td colspan='1' style=&quot;background-color: white; color:black; text-align: center;&quot;&gt;Revision as of 10:19, 4 October 2016&lt;/td&gt;
				&lt;/tr&gt;&lt;tr&gt;&lt;td colspan='2' style='text-align: center;' lang='en'&gt;&lt;div class=&quot;mw-diff-empty&quot;&gt;(No difference)&lt;/div&gt;
&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</summary>
		<author><name>Scipediacontent</name></author>	</entry>

	<entry>
		<id>http://www.colloquiam.com/wd/index.php?title=Cheng_et_al._2016aa&amp;diff=9457&amp;oldid=prev</id>
		<title>Scipediacontent: Created page with &quot;  '''Purpose:'''  We investigated the treatment outcome of testicular cancer in Taiwan, given globally rise in incidence in recent decades.        '''Materials and Methods:'''...&quot;</title>
		<link rel="alternate" type="text/html" href="http://www.colloquiam.com/wd/index.php?title=Cheng_et_al._2016aa&amp;diff=9457&amp;oldid=prev"/>
				<updated>2016-10-03T13:58:33Z</updated>
		
		<summary type="html">&lt;p&gt;Created page with &amp;quot;  &amp;#039;&amp;#039;&amp;#039;Purpose:&amp;#039;&amp;#039;&amp;#039;  We investigated the treatment outcome of testicular cancer in Taiwan, given globally rise in incidence in recent decades.        &amp;#039;&amp;#039;&amp;#039;Materials and Methods:&amp;#039;&amp;#039;&amp;#039;...&amp;quot;&lt;/p&gt;
&lt;p&gt;&lt;b&gt;New page&lt;/b&gt;&lt;/p&gt;&lt;div&gt;&lt;br /&gt;
&lt;br /&gt;
'''Purpose:'''  We investigated the treatment outcome of testicular cancer in Taiwan, given globally rise in incidence in recent decades.      &lt;br /&gt;
&lt;br /&gt;
'''Materials and Methods:'''  From February 2010 to October 2015, we retrospectively collected patients with the confirmed diagnosis of testicular cancer. Clinical data, pathological details and treatment outcomes were analyzed by reviewing medical records.      &lt;br /&gt;
&lt;br /&gt;
'''Results:'''  A total of 81 patients with testicular cancer were enrolled; 40 (49.4%) had seminoma and 41(50.6%) had non-seminoma germ cell cancer. The median age was 51 years old in seminoma and 30 years old in non-seminoma group. The median follow up period was 30 months (range 1 to 70).      &lt;br /&gt;
&lt;br /&gt;
The staging in seminoma group showed 36 (90%) stage I, 1 (2.5%) stage IS, 2 (5%) stage II and 1 (2.5%) stage III. The staging in non-seminoma group was 29 (70%) stage I, 4 (10%) stage IS, 3 (7%) stage II and 5 (12%) stage III. Approximately 97% of patients (35/36) with stage I seminoma and 90% (26/29) of patients with stage I non-seminoma accepted active surveillance. The overall recurrence rates were 12.5 % in seminoma and 31.7% in non-seminoma group. Only two patients in Non-seminoma group died of cancer. The 5-year recurrence free survival was 94.2% in seminoma and 84.2% in non-seminoma group. Five year overall survival yielded favorable results: 100% in seminoma and 94.2% in non-seminoma group.&lt;br /&gt;
&lt;br /&gt;
'''Conclusion:'''  Our study provided the latest evidence on oncological outcomes of testicular cancer. Active Surveillance in stage I testicular cancer yielded good prognosis and served as a treatment option.&lt;/div&gt;</summary>
		<author><name>Scipediacontent</name></author>	</entry>

	</feed>